ValiRx plc (LON:VAL – Get Free Report)’s stock price fell 9.7% during trading on Thursday . The stock traded as low as GBX 1.31 ($0.02) and last traded at GBX 1.31 ($0.02). 265,475 shares were traded during trading, a decline of 74% from the average session volume of 1,030,195 shares. The stock had previously closed at GBX 1.45 ($0.02).
ValiRx Stock Performance
The company has a current ratio of 2.64, a quick ratio of 1.27 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of £1.79 million, a price-to-earnings ratio of -67.50 and a beta of 0.59. The firm’s 50-day moving average is GBX 2.14 and its 200 day moving average is GBX 2.74.
ValiRx Company Profile
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Recommended Stories
- Five stocks we like better than ValiRx
- Earnings Per Share Calculator: How to Calculate EPS
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- How to Plot Fibonacci Price Inflection Levels
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- How to buy stock: A step-by-step guide for beginners
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.